tert-butyl (6-hydroxyhexyl)oxycarbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl (6-hydroxyhexyl)oxycarbamate
• 英文别名: N-Boc-6-aminoxyhexan-1-ol；6-(Tert-butyloxycarbonylaminooxy)hexan-1-ol；tert-butyl N-(6-hydroxyhexoxy)carbamate
• 化学式: C₁₁H₂₃NO₄
• 分子量: 233.308
• InChiKey: KCSNPYJVDNTZDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (6-hydroxyhexyl)oxycarbamate 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 6-Aminooxyhexyl 2-dodecylsulfanylcarbothioylsulfanyl-2-methylpropanoate
  参考文献：
  名称：

  Dynamic Covalent Diblock Copolymers Prepared from RAFT Generated Aldehyde and Alkoxyamine End-Functionalized Polymers

  摘要：

  Aldehyde- or alkoxyamine-containing trithiocarbonate chain transfer agents were prepared and used to mediate the synthesis of a series of polymers end-functionlized with either aldehyde or alkoxyamines functions, utilizing reversible addition-fragmentation polymerization techniques. Aldehyde end-functionalized polymers were shown to link through reversible oxime bond formation with alkoxyamine end-funtionalized polymers forming diblock copolymers. The dynamic nature of the oxime bond linking these polymer blocks together was demonstrated through a simple exchange reaction with a small molecule alkoxyamine. A diblock copolymer prepared from the self-assembly of an aldehyde end-functionalized polyisoprenc with an alkoxyamine end-functionalized polystyrene was shown to undergo further hierarchical self-assembly into micellar aggregates in DMF. It was shown that the addition of an excess of a small molecule alkoxyamine triggered the disassembly of these micelles.

  DOI：

  10.1021/ma902291a
• 作为产物：
  描述：

  6-溴正己醇 、 N-羟基氨基甲酸叔丁酯 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以80%的产率得到tert-butyl (6-hydroxyhexyl)oxycarbamate
  参考文献：
  名称：

  N-（叔丁氧基羰基）氨基氧基醚的简便合成

  摘要：

  通过用N-（叔丁氧基羰基）羟胺和DBU处理，可以将烷基碘化物和烷基溴化物方便地转化为N-保护的O-烷基氨基氧基化合物。该反应耐受羟基和羧酸酯，它们可以被进一步衍生化，因此可以用作许多官能化的O-烷基氨基氧基醚的前体。该反应可以纯净或以二氯甲烷为溶剂完成。

  DOI：

  10.1016/s0040-4039(99)02331-x

文献信息

• Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain
  作者：Xue Zhi Zhao、David Hymel、Terrence R. Burke

  DOI：10.1016/j.bmcl.2016.08.098

  日期：2016.10

  potent previously known polo-like kinase 1 (Plk1) polo-box domain (PBD) binding inhibitors. This improved binding may result by accessing a newly identified auxiliary region proximal to a key hydrophobic cryptic pocket on the surface of the protein. Our findings could have general applicability to the design of PBD-binding antagonists.

  通过涉及使用基于肟连接的策略初步筛选一组87个醛的过程，我们能够实现比最有效的先前已知的polo-like激酶1（Plk1）polo-box的亲和力提高数倍。域（PBD）结合抑制剂。这种改善的结合可以通过接近蛋白质表面上关键疏水隐窝的新近识别出的辅助区域来实现。我们的发现可能普遍适用于PBD结合拮抗剂的设计。
• Valency platform molecules comprising aminooxy groups
  申请人：——

  公开号：US20040224366A1

  公开（公告）日：2004-11-11

  Molecules comprising aminooxy groups are provided, wherein the aminooxy groups provide attachment sites for the covalent attachment of other molecules. In one embodiment, polyoxyethylene molecules comprising aminooxy groups are provided that can be conjugated to wide variety of biologically active molecules including poly(amino acids). In another embodiment, valency platform molecules comprising aminooxy groups are provided. The aminooxy groups can be used to form covalent bonds with biological molecules such as poly(amino acids). The aminooxy groups can, for example, react with poly(amino acids) modified to contain carbonyl groups, such as glyoxyl groups, to form a conjugate of the valency platform molecule and the biologically active molecule via an oxime bond. The valency platform molecules comprising aminooxy groups are advantageously reactive in the formation of conjugates, and they also can be readily synthesized to form a composition with very low polydispersity.

  提供了含有氨氧基团的分子，其中氨氧基团提供了其他分子的共价连接点。在一个实施例中，提供了含有氨氧基团的聚氧乙烯分子，可以与包括聚（氨基酸）在内的各种生物活性分子结合。在另一个实施例中，提供了含有氨氧基团的价平台分子。氨氧基团可以用于与生物分子（如聚（氨基酸））形成共价键。例如，氨氧基团可以与改性为含有羰基基团（如乙酰甘氨酸基团）的聚（氨基酸）反应，通过肟键形成价平台分子和生物活性分子的结合物。含有氨氧基团的价平台分子在形成结合物时具有优异的反应性，而且它们也可以容易地合成成具有非常低的多分散性的组合物。
• Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same
  申请人：Marquis M. David

  公开号：US20050004351A1

  公开（公告）日：2005-01-06

  The present invention provides domain 1 β 2 GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β 2 GPI polypeptides and mimetics. Domain 1 of β 2 GPI has been shown to bind to anti-cardiolipin (β 2 GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 β 2 GPI polypeptides may be used to detect β 2 GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 β 2 GPI polypeptides.

  本发明提供了1区β2GPI多肽、编码这些多肽的多核苷酸、这些多肽的类似物以及使用1区β2GPI多肽和类似物的方法。已经证明β2GPI的1区能够结合抗心磷脂（β2GPI依赖性抗磷脂抗体），这些抗体与多种病理学如血栓形成和胎儿流产有关。1区β2GPI多肽可用于检测样品中的β2GPI依赖性抗磷脂抗体。本发明还提供了使用这些1区β2GPI多肽诱导耐受的方法。
• Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
  申请人：Marquis David M.

  公开号：US06858210B1

  公开（公告）日：2005-02-22

  The present invention provides domain 1 β 2 GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 β 2 GPI polypeptides and mimetics. Domain 1 of β 2 GPI has been shown to bind to anti-cardiolipin (β 2 GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 β 2 GPI polypeptides may be used to detect β 2 GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 β 2 GPI polypeptides.

  本发明提供了领域1 β2GPI多肽，编码这些多肽的多核苷酸，这些多肽的类拟物和使用领域1 β2GPI多肽和类拟物的方法。已经证明β2GPI的领域1能够结合抗心磷脂（β2GPI依赖性抗磷脂抗体），这些抗体与多种病理学相关，例如血栓形成和胎儿流产。领域1 β2GPI多肽可用于检测样品中的β2GPI依赖性抗磷脂抗体。本发明还提供了使用这些领域1 β2GPI多肽诱导耐受的方法。
• THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME
  申请人：LA JOLLA PHARMACEUTICAL COMPANY

  公开号：EP1092027A1

  公开（公告）日：2001-04-18